Peter Altman net worth and biography

Peter Altman Biography and Net Worth

CEO of BioCardia
Dr. Altman has served as our President and CEO since 2002. He was CEO (1999 to 2003) and board member (1999 to 2014) of CareDx (NASDAQ: CDNA), a developer of a gene-based diagnostics for cardiac and other organ transplantation. He was CEO for Lumen Therapeutics from 2004 to 2005, an early-stage pharmaceutical company. He has extensive experience in life science research and product development, is named inventor in 45 U.S. patents, and has authored 40 scientific publications. Dr. Altman currently serves as a director on the board of Oncocyclist Biotech. He received his Ph.D. in Bioengineering/Pharmaceutical Chemistry from the University of California, San Francisco and University of California, Berkeley, his Management of Technology certificate from the Walter A. Haas School of Business at the University of California, Berkeley, and both his Master of Science and Bachelor of Science in Mechanical Engineering from the Columbia University School of Engineering and Applied Sciences. Dr. Altman has been elected Fellow of the American Heart Association.

What is Peter Altman's net worth?

The estimated net worth of Peter Altman is at least $637,187.18 as of September 23rd, 2022. Dr. Altman owns 328,447 shares of BioCardia stock worth more than $637,187 as of October 2nd. This net worth evaluation does not reflect any other assets that Dr. Altman may own. Additionally, Dr. Altman receives an annual salary of $488,060.00 as CEO at BioCardia. Learn More about Peter Altman's net worth.

How old is Peter Altman?

Dr. Altman is currently 55 years old. There are 3 older executives and no younger executives at BioCardia. Learn More on Peter Altman's age.

What is Peter Altman's salary?

As the CEO of BioCardia, Inc., Dr. Altman earned a total compensation package of $1,138,389.00 in 2021. Dr. Altman earned a salary of $488,060.00, stock awards of $114,334.00, options awards of $535,995.00, and no other miscellaneous compensation. Learn More on Peter Altman's salary.

How do I contact Peter Altman?

The corporate mailing address for Dr. Altman and other BioCardia executives is 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA, 94070. BioCardia can also be reached via phone at (650) 226-0120 and via email at [email protected] Learn More on Peter Altman's contact information.

Has Peter Altman been buying or selling shares of BioCardia?

Peter Altman has not been actively trading shares of BioCardia during the past quarter. Most recently, on Friday, September 23rd, Peter Altman bought 1,400 shares of BioCardia stock. The stock was acquired at an average cost of $1.87 per share, with a total value of $2,618.00. Following the completion of the transaction, the chief executive officer now directly owns 328,447 shares of the company's stock, valued at $614,195.89. Learn More on Peter Altman's trading history.

Are insiders buying or selling shares of BioCardia?

In the last twelve months, BioCardia insiders bought shares 8 times. They purchased a total of 33,148 shares worth more than $52,913.24. The most recent insider tranaction occured on September, 23rd when CEO Peter Altman bought 1,400 shares worth more than $2,618.00. Insiders at BioCardia own 23.3 % of the company. Learn More about insider trades at BioCardia.

Information on this page was last updated on 9/23/2022.

Peter Altman Insider Trading History at BioCardia

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/23/2022Buy1,400$1.87$2,618.00328,447View SEC Filing Icon  
9/21/2022Buy2,750$1.92$5,280.00323,947View SEC Filing Icon  
6/10/2022Buy4,500$1.46$6,570.00321,197View SEC Filing Icon  
5/13/2022Buy2,698$1.38$3,723.24348,143View SEC Filing Icon  
5/11/2022Buy1,000$1.30$1,300.00334,143View SEC Filing Icon  
4/28/2022Buy2,300$1.59$3,657.00330,443View SEC Filing Icon  
4/18/2022Buy13,500$1.39$18,765.00328,143View SEC Filing Icon  
11/18/2021Buy5,000$2.20$11,000.00View SEC Filing Icon  
8/17/2021Buy3,500$2.94$10,290.00232,909View SEC Filing Icon  
12/1/2020Buy1,000$2.49$2,490.00203,200View SEC Filing Icon  
11/27/2020Buy3,200$2.37$7,584.00203,200View SEC Filing Icon  
11/12/2020Buy2,000$2.07$4,140.00205,900View SEC Filing Icon  
11/10/2020Buy2,500$1.98$4,950.00203,900View SEC Filing Icon  
3/24/2020Buy1,200$2.90$3,480.00171,911View SEC Filing Icon  
3/19/2020Buy400$2.95$1,180.00170,711View SEC Filing Icon  
3/12/2020Buy3,400$3.15$10,710.00166,811View SEC Filing Icon  
6/5/2019Buy2,000$1.02$2,040.00View SEC Filing Icon  
5/28/2019Buy200$1.28$256.00View SEC Filing Icon  
5/17/2019Buy2,100$1.15$2,415.00View SEC Filing Icon  
5/1/2019Buy11,000$1.08$11,880.00View SEC Filing Icon  
2/13/2019Buy50$1.59$79.50View SEC Filing Icon  
11/16/2018Buy6,400$2.34$14,976.00View SEC Filing Icon  
11/13/2018Buy3,900$2.16$8,424.00View SEC Filing Icon  
11/9/2018Buy500$2.50$1,250.00View SEC Filing Icon  
11/2/2018Buy400$2.52$1,008.00View SEC Filing Icon  
10/30/2018Buy300$2.55$765.00View SEC Filing Icon  
10/26/2018Buy3,850$2.36$9,086.00View SEC Filing Icon  
9/20/2018Buy1,100$1.74$1,914.00View SEC Filing Icon  
9/18/2018Buy700$1.59$1,113.00View SEC Filing Icon  
9/12/2018Buy1,600$1.37$2,192.00View SEC Filing Icon  
9/5/2018Buy5,000$1.33$6,650.00View SEC Filing Icon  
8/27/2018Buy1,500$1.46$2,190.00View SEC Filing Icon  
6/11/2018Buy3,000$1.45$4,350.00View SEC Filing Icon  
4/18/2018Buy1,000$1.45$1,450.00View SEC Filing Icon  
3/20/2018Buy5,000$2.03$10,150.00View SEC Filing Icon  
See Full Table

Peter Altman Buying and Selling Activity at BioCardia

This chart shows Peter Altman's buying and selling at BioCardia by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BioCardia Company Overview

BioCardia logo
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
Read More

Today's Range

Now: $1.94
Low: $1.93
High: $2.10

50 Day Range

MA: $1.79
Low: $1.36
High: $2.09

2 Week Range

Now: $1.94
Low: $1.10
High: $3.16

Volume

116,045 shs

Average Volume

37,426 shs

Market Capitalization

$34.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22